Literature DB >> 31108012

Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes.

C S D Roxburgh1,2, P Strombom1, P Lynn1, A Cercek3, M Gonen4, J J Smith1, L K F Temple1, G M Nash1, J G Guillem1, P B Paty1, J Shia5, E Vakiani5, R Yaeger3, Z K Stadler3, N H Segal3, D Reidy3, A Varghese3, A J Wu6, C H Crane6, M J Gollub7, L B Saltz3, J Garcia-Aguilar1, M R Weiser1.   

Abstract

AIM: Significant recent changes in management of locally advanced rectal cancer (LARC) include preoperative staging, use of extended neoadjuvant therapies and minimally invasive surgery (MIS). This study was aimed at characterizing these changes and associated short-term outcomes.
METHOD: We retrospectively analysed treatment and outcome data from patients with T3/4 or N+ LARC ≤ 15 cm from the anal verge who were evaluated at a comprehensive cancer centre in 2009-2015.
RESULTS: In total, 798 patients were identified and grouped into five cohorts based on treatment year: 2009-2010, 2011, 2012, 2013 and 2014-2015. Temporal changes included increased reliance on MRI staging, from 57% in 2009-2010 to 98% in 2014-2015 (P < 0.001); increased use of total neoadjuvant therapy, from 17% to 76% (P < 0.001); and increased use of MIS, from 33% to 70% (P < 0.001). Concurrently, median hospital stay decreased (from 7 to 5 days; P < 0.001), as did the rates of Grade III-V complications (from 13% to 7%; P < 0.05), surgical site infections (from 24% to 8%; P < 0.001), anastomotic leak (from 11% to 3%; P < 0.05) and positive circumferential resection margin (from 9% to 4%; P < 0.05). TNM downstaging increased from 62% to 74% (P = 0.002).
CONCLUSION: Shifts toward MRI-based staging, total neoadjuvant therapy and MIS occurred between 2009 and 2015. Over the same period, treatment responses improved, and lengths of stay and the incidence of complications decreased. Colorectal Disease
© 2019 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Complications; MRI; Minimally invasive surgery; Rectal cancer; Response to treatment; Total neoadjuvant therapy

Year:  2019        PMID: 31108012      PMCID: PMC6773478          DOI: 10.1111/codi.14713

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  39 in total

1.  Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

Authors:  Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

Review 2.  Fast track surgery versus conventional recovery strategies for colorectal surgery.

Authors:  Willem R Spanjersberg; Jurrian Reurings; Frederik Keus; Cornelis Jhm van Laarhoven
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

3.  Developing a robotic colorectal cancer surgery program: understanding institutional and individual learning curves.

Authors:  Hamza Guend; Maria Widmar; Sunil Patel; Garrett M Nash; Philip B Paty; José G Guillem; Larissa K Temple; Julio Garcia-Aguilar; Martin R Weiser
Journal:  Surg Endosc       Date:  2016-11-04       Impact factor: 4.584

4.  Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.

Authors: 
Journal:  BMJ       Date:  2006-09-19

5.  Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

Authors:  Andrea Cercek; Karyn A Goodman; Carla Hajj; Emily Weisberger; Neil H Segal; Diane L Reidy-Lagunes; Zsofia K Stadler; Abraham J Wu; Martin R Weiser; Philip B Paty; Jose G Guillem; Garrett M Nash; Larissa K Temple; Julio Garcia-Aguilar; Leonard B Saltz
Journal:  J Natl Compr Canc Netw       Date:  2014-04       Impact factor: 11.908

6.  High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?

Authors:  Joo Hee Kim; Geerard L Beets; Myeong-Jin Kim; Alfons G H Kessels; Regina G H Beets-Tan
Journal:  Eur J Radiol       Date:  2004-10       Impact factor: 3.528

7.  Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging.

Authors:  Dow-Mu Koh; Ian Chau; Diana Tait; Andrew Wotherspoon; David Cunningham; Gina Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

8.  Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial.

Authors:  Andrew R L Stevenson; Michael J Solomon; John W Lumley; Peter Hewett; Andrew D Clouston; Val J Gebski; Lucy Davies; Kate Wilson; Wendy Hague; John Simes
Journal:  JAMA       Date:  2015-10-06       Impact factor: 56.272

9.  Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.

Authors:  Seung-Yong Jeong; Ji Won Park; Byung Ho Nam; Sohee Kim; Sung-Bum Kang; Seok-Byung Lim; Hyo Seong Choi; Duck-Woo Kim; Hee Jin Chang; Dae Yong Kim; Kyung Hae Jung; Tae-You Kim; Gyeong Hoon Kang; Eui Kyu Chie; Sun Young Kim; Dae Kyung Sohn; Dae-Hyun Kim; Jae-Sung Kim; Hye Seung Lee; Jee Hyun Kim; Jae Hwan Oh
Journal:  Lancet Oncol       Date:  2014-05-15       Impact factor: 41.316

10.  Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer.

Authors:  D Pettersson; E Lörinc; T Holm; H Iversen; B Cedermark; B Glimelius; A Martling
Journal:  Br J Surg       Date:  2015-07       Impact factor: 6.939

View more
  2 in total

1.  Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.

Authors:  Walid K Chatila; Jin K Kim; Henry Walch; Michael R Marco; Chin-Tung Chen; Fan Wu; Dana M Omer; Danny N Khalil; Karuna Ganesh; Xuan Qu; Anisha Luthra; Seo-Hyun Choi; Yu-Jui Ho; Ritika Kundra; Katharine I Groves; Oliver S Chow; Andrea Cercek; Martin R Weiser; Maria Widmar; Iris H Wei; Emmanouil P Pappou; Garrett M Nash; Philip B Paty; Qian Shi; Efsevia Vakiani; S Duygu Selcuklu; Mark T A Donoghue; David B Solit; Michael F Berger; Jinru Shia; Raphael Pelossof; Paul B Romesser; Rona Yaeger; J Joshua Smith; Nikolaus Schultz; Francisco Sanchez-Vega; Julio Garcia-Aguilar
Journal:  Nat Med       Date:  2022-08-15       Impact factor: 87.241

2.  Comparing outcomes of robotic versus open mesorectal excision for rectal cancer.

Authors:  Rosa M Jimenez-Rodriguez; Jessica Flynn; Sujata Patil; Maria Widmar; Felipe Quezada-Diaz; Patricio Lynn; Paul Strombom; Larissa Temple; Joshua J Smith; Iris H Wei; Emmanouil P Pappou; Jose G Guillem; Philip P Paty; Garrett M Nash; Martin R Weiser; Julio Garcia-Aguilar
Journal:  BJS Open       Date:  2021-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.